ATR and gastric cancer: Notably, ARID1A mutations, frequently observed in gastric cancer and particularly enriched in the TCGA genomically stable and Epstein–Barr virus (EBV)-positive subtypes, have been linked to altered chromatin remodeling, impaired DNA repair, and increased RS, molecular hallmarks that may confer heightened vulnerability to ATR blockade.